Liposome drug delivery can address formulation challenges that limit the development of conventional dosage forms. Liposomes can encapsulate both hydrophilic and hydrophobic drug molecules within a lipid-based structure, creating opportunities to improve drug delivery, protect sensitive molecules, and influence drug release.
For pharmaceutical developers working with poorly soluble, highly potent, or otherwise challenging molecules, liposome formulation development requires careful control of lipid composition, particle size, encapsulation efficiency, drug loading, stability, and release characteristics. The formulation must also be designed with eventual manufacturing requirements in mind.
Ascendia Pharmaceutical Solutions provides lipid-based formulation development and manufacturing capabilities through its proprietary LipidSol® technology, supported by analytical characterization, scale-up, and cGMP manufacturing capabilities.
Liposomes are lipid-based vesicles characterized by a bilayer structure that can encapsulate drug molecules. The structure contains an aqueous interior and a hydrophobic lipid membrane, allowing liposomes to accommodate different types of drug molecules.
Hydrophilic compounds can be incorporated into the aqueous interior, while hydrophobic compounds can associate with the lipid bilayer. This structural flexibility makes liposomes useful for pharmaceutical drug delivery applications involving molecules with different physicochemical properties. Ascendia Pharmaceutical Solutions’ LipidSol® technology encompasses liposomes and other lipid nanoparticle structures designed to accommodate different therapeutic modalities.
Liposomes can also be engineered with different lipid compositions and surface characteristics to influence stability, circulation time, drug release, and interactions with biological systems.
The specific composition matters because the lipid bilayer is not simply a container for the drug. It is an engineered component of the drug delivery system that influences how the formulation behaves during manufacturing, storage, administration, and delivery.
Conventional dosage forms are not appropriate for every drug candidate. Poor aqueous solubility, limited bioavailability, and high potency can create formulation and safety challenges that require alternative delivery strategies. Depending on the physicochemical properties of the API, lipid-based formulation technologies can provide an alternative approach for improving solubility, bioavailability, stability, and drug delivery.
Liposomes can provide a means of encapsulating molecules that present these challenges. This is particularly relevant for highly potent or cytotoxic compounds, including certain oncology therapies, where controlling drug distribution and exposure can be an important part of formulation development.
Lipid-based delivery systems can also protect encapsulated molecules and influence how they interact with biological tissues. Depending on the formulation design, liposomes can be engineered for characteristics such as longer circulation or altered delivery with receptors to specific tissues.
Ascendia Pharmaceutical Solutions has explored lipid-based delivery approaches for oncology applications where poor solubility, high potency, systemic toxicity, and limited bioavailability can create barriers to development. Its nanotechnology in oncology content provides additional insight into how LipidSol® can be applied to these formulation challenges.
Developing a liposomal drug product is more complex than combining a drug with lipids. The formulation must achieve a defined set of physical, chemical, and performance characteristics through enhanced permeation and retention (EPR) mechanism.
Lipid composition is one of the most important variables. Phospholipids can have different fatty acid chain lengths and headgroups that influence the organization and stability of the bilayer. Cholesterol can also be incorporated into the membrane to modify its structure and improve stability. In addition, the headgroups can be modified with low molecular weight polyethylene glycols (PEGs) to enhance circulation time.
Particle size is another critical consideration. Liposomes can range from tens of nanometers to much larger structures, depending on the formulation and manufacturing process. Particle size and size distribution can influence physical stability, drug release, biodistribution, and other product characteristics.
Encapsulation efficiency and drug loading must also be evaluated. A formulation needs to consistently incorporate the intended amount of drug while maintaining the desired physical and chemical characteristics.
These variables are interconnected. Changing one component of the formulation can affect particle size, stability, encapsulation, release, or other critical quality attributes.
Ascendia Pharmaceutical Solutions’ LipidSol® technology provides a broader look at the different lipid structures and compositions that can be considered when developing lipid-based drug delivery systems.
Stability can be one of the most difficult aspects of liposome drug delivery.
Liposomes are dynamic structures, and maintaining their physical and chemical integrity during storage requires careful formulation design. Potential concerns include drug leakage, degradation of the encapsulated molecule, changes in particle characteristics, and changes to the lipid bilayer.
Drug leakage is particularly important. If an encapsulated drug begins to leave the liposome during storage, the formulation can develop different populations of drug: encapsulated drug and free drug. For highly potent or cytotoxic molecules, changes in the amount of free drug can have important implications for product performance and safety. Lyophilization is needed to further enhance the stability and shelf life of liposomal drug products.
The lipid composition plays a significant role in addressing these challenges. Lipids with longer hydrocarbon chains can form more stable bilayer structures than shorter-chain lipids, while cholesterol can be incorporated into the bilayer to influence membrane rigidity and reduce leakage.
Formulation screening can help identify the lipid composition that provides the appropriate balance of stability, encapsulation, drug release, and other performance requirements.
Liposome formulation development requires analytical methods capable of measuring the characteristics that determine whether a formulation is performing as intended.
Particle size distribution (PSD) and polydispersity index (PDI), and surface charges measured as zeta potential provide information about the physical characteristics of the liposomal population. Assay testing can determine drug concentration and integrity, while encapsulation efficiency determines how much drug is contained within the liposome compared with the amount remaining outside the vesicles.
In vitro drug release testing, typically accomplished by dialysis, provides another important measure of performance. The formulation can be evaluated to determine how quickly the drug is released and whether the release profile meets the intended product requirements.
Stability studies then assess how these characteristics change over time.
Together, these analytical measurements provide the data needed to understand the relationship between formulation composition, manufacturing process, product quality, and performance.
Ascendia Pharmaceutical Solutions recently examined the importance of analytical rigor, stability, and scalable formulation, emphasizing how analytical and stability data can influence formulation decisions before problems become more difficult to address.
A liposome formulation that performs well at laboratory scale still needs to demonstrate that it can be produced consistently at larger scale.
Small-scale screening - can use techniques such as sonication, vortex mixing, and mechanical mixing to evaluate formulations. Larger-scale manufacturing requires greater process control, particularly when particle size, encapsulation efficiency, drug loading, and batch-to-batch consistency are critical.
Microfluidic and extrusion technologies can provide tighter control over liposome assembly and particle characteristics during scale-up. Ascendia Pharmaceutical Solutions has developed lipid nanoparticle processing capabilities that support controlled particle formation and scale-up.
The manufacturing process must also account for materials, solvents, mixing conditions, processing parameters, solvent and free drug removal by tangential flow filtration (TFF), and the requirements associated with GMP production.
Designing for scale early in development can reduce the risk of discovering manufacturing limitations after significant development work has already been completed. A well-defined scale-up strategy should maintain alignment between formulation composition, process parameters, and product performance as a program moves from development toward GMP manufacturing.
Liposomes are one type of lipid-based nanoparticle architecture, but the terms liposome and lipid nanoparticle should not be treated as interchangeable.
Classical liposomes have a defined lipid bilayer surrounding an aqueous interior. Other lipid nanoparticle systems can use different internal structures and compositions, including solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), lipoplexes, non-lamellar cubosomes and other hybrid-polymer and lipid-based micellar assemblies.
The structural differences can influence payload capacity, stability, release, cellular interactions, and manufacturing requirements.
Ascendia Pharmaceutical Solutions’ LipidSol® platform encompasses multiple lipid-based assemblies, including traditional liposomes, solid lipid nanoparticles, nanostructured lipid carriers, lipoplexes, and other structures. This allows development teams to evaluate multiple lipid-based approaches when a conventional liposome is not the optimal solution for a particular molecule.
The same principles of lipid selection, particle engineering, and payload protection become particularly important when developing lipid nanoparticle delivery systems for complex therapeutic modalities, including nucleic acids.
The lipid composition and surface characteristics can be modified to influence how the particles behave in the body. For example, PEGylated phospholipids can be used to develop stealth liposomes designed for longer circulation by reducing uptake by the reticuloendothelial system.
Surface modification can also be explored when targeting specific tissues is part of the development strategy. Ascendia Pharmaceutical Solutions’ LipidSol® technology includes lipid structures designed for applications involving controlled delivery and longer circulation.
These approaches demonstrate why liposome development requires formulation expertise rather than a standardized recipe. The appropriate formulation depends on the drug molecule, intended route of administration, target product profile, desired release characteristics, stability requirements, and manufacturing process.
Liposome development requires capabilities that extend beyond conventional formulation development.
Sponsors evaluating a CDMO should consider whether the organization has the right expertise with lipid-based formulations, equipped with appropriate analytical capabilities, and specialized nanoparticle processing equipment, scale-up expertise, and cGMP aseptic manufacturing capabilities.
An integrated development model can also reduce the risks associated with transferring a formulation from one organization for development to another organization for manufacturing. Ascendia Pharmaceutical Solutions supports programs from pre-formulation and formulation development through stability studies, analytical testing, and cGMP manufacturing.
Access to multiple technology platforms can provide additional flexibility. If a conventional liposome does not provide the required drug loading, stability, release profile, or delivery characteristics, other lipid-based assemblies may warrant evaluation.
This type of formulation strategy is particularly relevant for complex molecules where the optimal delivery system cannot be determined without screening multiple formulation variables.
Ascendia Pharmaceutical Solutions combines lipid-based formulation expertise with LipidSol® technology, analytical characterization, scale-up capabilities, and cGMP aseptic manufacturing, coupled with lyophilization capabilities.
LipidSol® is designed to encapsulate small and large molecules and biologics within lipid nanoparticle structures. The platform includes traditional liposomes as well as other lipid-based assemblies that can address different drug delivery requirements.
Ascendia Pharmaceutical Solutions also supports the transition from formulation development to manufacturing. Its broader lipid nanoparticle capabilities include formulation development, analytical characterization, microfluidic processing, scale-up, and cGMP manufacturing.
The combination of formulation science and manufacturing capabilities can help sponsors address development challenges before they become manufacturing problems.
Liposome drug delivery can provide pharmaceutical developers with an alternative approach for molecules that present solubility, bioavailability, potency, stability, or delivery challenges. Success depends on more than selecting a lipid and encapsulating the drug. Lipid composition, particle characteristics, encapsulation efficiency, stability, analytical methods, manufacturing process, and scale-up strategy all require careful consideration for a robust liposomal drug product.
Ascendia Pharmaceutical Solutions provides the formulation development, LipidSol® technology, analytical, scale-up, and cGMP manufacturing capabilities needed to advance complex lipid-based drug delivery programs.
Pharmaceutical and biotechnology companies developing liposomal formulations can contact Ascendia Pharmaceutical Solutions to discuss program requirements, evaluate formulation strategies, and schedule a meeting with the development team.